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ABSTRACT
Objective: The aim of this study was to investigate the combined influence of three independent variables in the preparation of atorvastatin 
proniosomes by coacervation-phase separation method.
Methods: On the basis of the preliminary trials, a 3-factor, 3-level Box–Behnken design was employed to study the effect of cholesterol, soya lecithin, 
and Span 60 independent variable on dependent variables (particle size and % entrapment efficiency). Transmission electron microscopy analysis of 
optimized formulation has demonstrated the presence of individual proniosomes in spherical shape.
Results: Atorvastatin optimized proniosomal formulation F2 shown better particle size and % entrapment efficiency, and also, the drug release was 
99.72% within 24 h in slow and controlled manner when compared with control. Kinetic analysis of drug release profiles showed that the drug release 
was followed by zero-order manner with Korsmeyer–Peppas model, which implies super case II release kinetics. The particle size and zeta potential 
of the optimized atorvastatin proniosomal gel were found to be 65.72 and −10.5, respectively. The optimized batch of proniosomes was used for the 
preparation of atorvastatin-based proniosomal hydrogel by incorporating hydrated proniosomes to carbopol matrix to enhance the stability and 
viscosity of the system.
Conclusion: The enhanced skin permeation, for a prolonged period of time, may lead to improved efficacy and better patient compliance. This study 
suggests that proniosomal gel-containing atorvastatin could perform therapeutically better effects than the conventional formulations.
Keywords: Atorvastatin, Proniosomes, Box–Behnken Design, Span 60, Zeta potential.
INTRODUCTION
Drug delivery systems using colloidal particulate carriers such as 
liposomes or niosomes have distinct advantages over conventional 
dosage forms because the particles can act as drug-containing 
reservoirs [1]. The use of non-ionic surfactant vesicles (niosomes) 
as drug carrier systems has distinct advantages over conventional 
dosage [2]. They can increase the drug efficacy, reduce drug side effects, 
increase the drug solubility, and develop an effective topical delivery [3]. 
Transdermal drug delivery system is among the most widely employed 
system to overcome the issues associated with oral route, increases 
the therapeutic efficacy of many drugs by preventing their conversion 
to undesirable metabolites, and also helps in maintaining uniform 
plasma levels in vivo [4]. Due to which, it exhibits a high level of patient 
compliance with low levels of intra- and inter-patient variability [5]. 
Among various strategies, vesicular systems such as niosomes exhibit 
substantial potential to overcome such barrier [6,7]. Proniosomal gel 
when applied to skin under occlusive conditions get hydrated with 
the skin moisture and converted to niosomes [8]. The additional 
convenience of the transportation, distribution, storage, and dosing 
would make “dry niosomes” a promising industrial product. These 
dry niosomes are hydrated immediately before use and thus avoids 
some of the problems [9,10] Atorvastatin calcium is a 5-hydroxy-3-
methylglutaryl-coenzyme A reductase inhibitor used in the treatment 
of hyperlipidemia [11]. It has an oral bioavailability of <12%. It also 
undergoes high first-pass metabolism. It is highly soluble in acidic pH 
and absorbed more in the upper part of the gastrointestinal tract [12].
In the present study, the coacervation-phase separation method was 
used for the preparation and optimization of atorvastatin proniosomes, 
from a technical viewpoint, and allowed a wider scope to be used to 
study the influence of various formulation variables. To enhance the 




Atorvastatin calcium was received as a gift sample from Aurobindo 
Pharma Ltd., Hyderabad. Span 60 and soya lecithin were purchased 
from SD Fine Chemicals (Mumbai, India). Cholesterol 95% stabilized 
was purchased from Acros Organics. Carbopol P 934 was obtained from 
MSN Laboratories, Hyderabad. Dialysis tubing was purchased from 
HiMedia Laboratories (Mumbai, India). All other chemicals and solvents 
were of analytical grade and were used without further purification.
Methodology
Drug-excipient compatibility study
Fourier-transform infrared (FTIR) studies
The drug-excipient compatibility studies were performed to check 
the interaction between drug and excipients. The FTIR spectra of 
drug sample and its physical mixture with excipients were carried 
out by potassium bromide disc method using Shimadzu IRAffinity 1 
Spectrophotometer in the region of 4000–400 cm−1.
Differential scanning calorimetry (DSC) studies
DSC of drug sample and its physical mixture with excipients was carried 
out using a Perkin Elmer DSC-7 Differential Scanning Calorimeter 
(PerkinElmer, CT, USA) equipped with a TAC 7/DX Instrument 
Controller. Analyses were performed in triplicate on 5 mg samples 
under nitrogen purge.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i4.26707
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Design of experiments
Initially, preliminary experiments (one factor at a time approach) were 
performed to determine the main factors and the appropriate ranges in 
which the optima lie. Among all the non-ionic surfactants, Span 60 was 
selected based on the results of the preliminary experiments. Further, 
the effect of three factors (concentrations of surfactant, cholesterol, 
and soya lecithin) on the particle size and % entrapment efficiency 
was tested. Through preliminary screening, the concentrations of 
surfactant, cholesterol, and soya lecithin were identified as the most 
significant variables within the range of 100–300 mg, 10–50mg, and 
50–200 mg, respectively.
On the basis of the preliminary trials, a 3-factor, 3-level Box–Behnken 
design was employed to study the effect of each independent variable 
on dependent variables (particle size and % entrapment efficiency). The 
independent factors and the dependent variables used in the design are 
listed in Table 1. The experiments were conducted on the basis of the 
design, and the obtained responses for the dependent variables are given 
in Table 2. The response surfaces of the variables inside the experimental 
domain were analyzed using Stat-Ease Design-Expert® software 
V8.0.1. Subsequently, three additional confirmation experiments were 
conducted to verify the validity of the statistical experimental strategies.
Preparation of proniosomes
Atorvastatin proniosomes were prepared by coacervation-phase 
separation method [14]. The non-ionic surfactant, cholesterol, and soya 
lecithin were taken in an appropriate amount as shown in Table 2. All 
the components were taken in a wide mouth glass tube and dissolved 
in ether. The drug, atorvastatin 10 mg was dissolved in ethanol (2.5 ml). 
After mixing all ingredients, the open end of the glass vial was covered 
with a lid to prevent loss of solvent, and the glass vial warmed in a 
water bath at 65±3°C to dissolve all the ingredients. The aqueous 
phase (0.1% glycerol solution) was added and warmed in a water 
bath until a clear solution is formed which, on cooling, converted into 
a proniosomal gel. The gel obtained was preserved in the same glass 
tubes in the dark for characterization. The proniosomal structure was 
a liquid crystalline-compact proniosomal hybrid that was converted 
into proniosomes on hydration. The system was hydrated by 10 ml of 
phosphate buffer (pH 7.4) under sonication (Ultrasonic Bath Sonicator, 
Make – Frontline Electronics, Model – FS-2) at 37°C.
Characterization of proniosomal gel
Surface morphology
Surface morphology of proniosomal gel was performed using optical 
microscopy. A drop of dispersion was taken on a glass slide without 
a cover slip, and the process of proniosomal formation was observed 
through an optical microscope (Labomed) and photographs were taken 
by digital camera [15,16].
Entrapment efficiency
The entrapment efficiency was determined by separating the 
unentrapped drug. Proniosomal gel (100 mg) was hydrated with 
10 ml of distilled water by manual shaking for 5 min to form niosomal 
dispersion. The percentage entrapment efficiency of atorvastatin in 
hydrated proniosomes was determined by centrifugation technique, 
which was centrifuged at 14,000 rpm, at 4°C for 30 min, and the 
supernatant containing unentrapped drug was withdrawn and 
analyzed for free drug content by measuring absorbance at λmax 246 nm 
using ultraviolet (UV) spectrophotometer [17,18].
Particle size and size distribution analysis
For all the batches of proniosomes, particle size analysis was carried 
out using Malvern Zetasizer Nano ZS (Malvern Instruments, UK).
Table 1: List of dependent and independent variables in Box–Behnken design
Variable Name Units Levels
Low Middle High
Independent variables
A Concentration of surfactant (Span 60) mg 100 200 300
B Concentration of cholesterol mg 10 30 50
C Concentration of soya lecithin mg 50 125 200
Dependent variable Goal
Y1 Particle size nm Minimize 
Y2 Entrapment efficiency % Maximize
Table 2: Box–Behnken experimental design and observed responses
Run Factor A Concentration 
of surfactant (Span 60)
Factor B Concentration 
of cholesterol






1 200 30 125 73.21 93.23
2 100 30 50 64.68 76.12
3 200 50 200 156.72 64.32
4 200 30 125 72.48 93.82
5 300 30 200 182.18 79.34
6 300 30 50 161.72 81.12
7 300 10 125 158.12 96.12
8 100 10 125 67.12 92.34
9 200 10 200 198.12 91.82
10 300 50 125 178.1 62.18
11 100 50 125 86.1 56.1
12 100 30 200 97.46 69.17
13 200 30 125 73.46 93.12
14 200 30 125 72.69 92.86
15 200 50 50 102.56 59.72
16 200 30 125 73.12 93.46
17 200 10 50 88.72 91.74
*Each formulation containing atorvastatin calcium 10 mg
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Scanning electron microscopy (SEM)
SEM was applied to assess the shape and surface morphology of 
microspheres (HITACHI, S-3700N) [19].
Transmission electron microscopy (TEM) analysis of proniosomes
The morphology of the prepared proniosomes was observed under 
TEM (JEM-2000 EXII; JEOL, Tokyo, Japan). One drop of diluted 
atorvastatin pronosomal suspension was deposited on a film-
coated copper grid and stained with one drop of 2% (w/v) aqueous 
solution of phosphotungstic acid and then allowed to dry for contrast 
enhancement. The samples were examined at the magnification of 
72000× by TEM [20].
In vitro drug release studies
In vitro release studies of hydrated atorvastatin proniosomal dispersions 
were done using lab-made static Franz glass diffusion cells. The dialysis 
membrane was hydrated in the receptor medium, which consisted 
of a phosphate buffer pH 6.8, for 24h before mounting into a Franz 
diffusion cell. A 2.5ml hydrated atorvastatin proniosomal dispersion 
was placed in the donor chamber and the receptor chamber was filled 
with 7.5ml receptor medium and stirred continuously at 100rpm at 
37°C, and the samples were withdrawn at different time intervals for 
24 h from the receptor chamber through a side-arm tube. After each 
withdrawal of sample, an equal volume of receptor medium was added 
to the receptor chamber to maintain a constant volume throughout the 
study. The samples were analyzed for atorvastatin concentration using 
UV spectrophotometry at λmax 244 nm, and measurements were carried 
out in triplicate [21,22].
Drug release kinetics
To elucidate the mode and mechanism of drug release, the data from 
the in vitro release study were fitted into various kinetic models, such 
as zero-order, first-order, Higuchi’s, and Korsmeyer–Peppas model [23].
Stability studies
The stability study was performed according to the ICH guidelines. The 
proniosomal gel formulations were filled in tightly closed glass vials and 
subjected to stability testing. The formulations were kept at refrigerated 
conditions (4±1°C) and room temperature (25±2°C) and were analyzed 
for particle size and entrapment efficiency after 3 months [24].
Formulation of atorvastatin-based proniosomal hydrogel
Based on the characterization and the particle size, highest entrapment 
efficiency and high % of drug release, F2 was selected. The selected F2 
hydrated proniosomal formulation was formulated into hydrogel by 
adding 1% (w/w) Carbopol P 934 under magnetic stirring at 800rpm. 
Stirring was continued until carbopol was dispersed. The dispersions 
were neutralized using triethanolamine solution [25].
Viscosity measurements
The flow behavior and viscosity of the tested formulations were 
determined using LV III rotating Brookfield Viscometer using Spindle 
RV-3 (Brookfield Engineering Laboratories Inc., Stoughton, MA, USA).
Ex vivo permeation study
Ex vivo permeation study was carried out using male Wistar rat skin as 
reported by Ibrahim et al. [26]. The rat skin was mounted between the 
donor and receptor compartment with the stratum corneum facing the 
upper side on the Franz diffusion cell and phosphate buffer pH 6.8 was 
taken in receptor compartment. The temperature was maintained at 
37±1°C. Proniosomal formulation equivalent to 10 mg of atorvastatin was 
spreaded over the rat skin. The receptor compartment content was stirred 
with the help of magnetic beads. The samples were collected at different 
time intervals and were immediately replaced with the fresh media. The 
samples were analyzed for drug content using UV spectrophotometer 
at 244 nm. The cumulative amount of drug permeated (Q) at different 
time intervals and various parameters such asss steady-state flux (Jss), 
permeability coefficient (Kp), and enhancement ratio were studied.
Skin irritation study of proniosomal hydrogel
About 0.5 g proniosomal gel was applied to three rats on an area of skin 
approximately 1” × 1” (2.54 × 2.54 cm) square. Animals were returned 
to their cages. After a 24 h exposure, the proniosomal gel was removed. 
The test sites were wiped with tap water to remove any remaining test 
article residue [27].
Data analysis
Data were expressed as the mean±standard deviation of the mean, 
and a statistical analysis was carried out by employing the one-way 
analysis of variance (ANOVA). A value of p<0.05 was considered to be 
statistically significant.
RESULTS AND DISCUSSION
Preparation of atorvastatin proniosomes
In this study, the proniosomes of atorvastatin were formulated, 
optimized, and evaluated for its efficacy in transdermal drug delivery to 
overcome the major issues associated with its oral delivery.
Drug-excipient compatibility study
FTIR studies
The FTIR spectra of pure atorvastatin calcium (Fig. 1) showed 
characteristic peaks at 1381 cm−1 (C-N-stretching), 2965.15 cm−1 
(C-H-stretching), 1315.56 cm−1 (C-HO-stretching alcoholic group), 
1564.97 cm−1 (C=O-stretching amidic group), 3403.27 cm−1 (N-H-
stretching), 1775.97 cm−1 (C=C-bending), 751.62 cm−1 696.95 cm−1 (C-F-
stretching), and 1104.39 cm−1 (O-H-bending). The FTIR spectra of the 
physical mixture were having similar fundamental peaks and pattern 
when compared with the pure drug. Thus, there are no significant 
interactions among the drug and excipients.
Fig. 1: Fourier-transform infrared spectrum of atorvastatin pure drug
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DSC studies
DSC thermogram of atorvastatin calcium (Fig. 2) was presented in 
crystal structure exhibiting sharp melting peaks at 159.7. The DSC 
thermogram endothermic peak of atorvastatin calcium (Fig. 3) was 
disappeared in atorvastatin calcium-loaded proniosomes, which 
ensures that the drug is completely encapsulated and homogeneously 
dispersed in the proniosomes. The absence of atorvastatin peak on 
this thermogram has been taken to represent the only evidence of 
atorvastatin amorphization. The physical state of the drug inside the 
carrier system is important because it can affect the in vitro and in vivo 
drug release. The amorphous atorvastatin may be favorable due to the 
enhanced solubility of the active agent.
Optimization of formulation variables
Through preliminary experiments, the concentration of surfactant (a), 
concentration of cholesterol (b), and concentration of soya lecithin 
(c) were identified as the most significant variables influence the 
particle size and entrapment efficiency. The formulations were further 
optimized by considering the parameters such as smaller particle size 
and maximum entrapment efficiency.
Seventeen experiments were required for the response surface 
methodology based on the Box–Behnken design. Based on the 
experimental design, the factor combinations yielded different responses 
as presented in Table 2. These results clearly specify that the dependent 
variables are strongly dependent on the selected independent variables 
as they show a wide variation among all the 17 batches. Data were 
analyzed using Stat-Ease Design-Expert® software V8.0.1 to obtain 
ANOVA, regression coefficients, and regression equation. Mathematical 
relationships were generated using multiple linear regression analysis for 
the mentioned variables as shown in Table 3. These equations represent 
the quantitative effect of concentration of surfactant (a), concentration of 
cholesterol (b), and concentration of soya lecithin (c) and their interaction 
on particle size (Y1) and entrapment efficiency (Y2). The values of the 
coefficients of A, B, and C are related to the effect of these variables on 
the responses Y1 and Y2 (Tables 3 and 4), and coefficients with more 
than one-factor term and those with higher order terms represent 
interaction terms and quadratic relationship, respectively. A positive sign 
represents synergistic effect, while a negative sign indicates antagonistic 
effect. A backward elimination procedure was adopted to fit the data to 
the quadratic model. Both the polynomial equations were found to be 
statistically significant (p\0.01), as determined using ANOVA as per the 
provisions of Design-Expert software.
The mathematical model generated for particle size (Y1) was found to be 
significant with F-value of 21.03, implying that the model is significant . 
There is only a 0.01% chance that a “model F-value”  could occur due to 
noise (p <0.0001) and R2 value of 0.9424. The independent variables such 
as A, B, and C and the quadratic term of BC, A2, B2, and C2 have significant 
effects on the particle size since p<0.0001 represents the significant 
model terms. Results of the equation indicate that the effect of A is more 
significant than B and C. The influence of the main and interactive effects 
Fig. 2: Fourier-transform infrared spectrum of atorvastatin physical mixture
Fig. 3: Differential scanning calorimetry thermograms of (A) pure atorvastatin calcium and (B) atorvastatin physical mixture
Table 3: Regression equations for the responses – Particle size 
and entrapment efficiency
Response Regression equation
Y1 72.99+45.60 A+1.43 B+27.10 C - 13.81BC 
+19.67A2+29.69 B2+33.84 C2
Y2 93.30+3.13 A - 16.21 B - 0.51 C - 8.54 A2-8.08 
B2-8.32 C2
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of independent variables on the particle size was further elucidated 
using the perturbation and three-dimensional (3D) response surface 
plots. The perturbation plot (Fig. 4) shows the main effects of A, B, and 
C on the particle size (Y1). This figure clearly shows that A has the main 
and major effect on Y1, followed by C which has a moderate effect on Y1, 
followed by B which has a little effect on Y1. The relationship between the 
dependent and independent variables was further elucidated using 3D 
response surface plots. Fig. 5 shows the interactive effect of B and C on 
the particle size (Y1) at a fixed level of C. At low levels of A (concentration 
of surfactant), Y1 increases from 64.68 nm to 97.46 nm. Similarly, at high 
levels of A, Y1 increases from 158.12 nm to 182.18 nm.
Entrapment efficiency of proniosomes was found to be in the range of 
56.1–96.12% as shown in Table 2.
The polynomial equation for entrapment efficiency exhibited a good 
correlation coefficient (0.9832) and the model F-value of 97.77 implies 
that the model is significant. There is only a 0.01% chance that a 
“model F-value” could occur due to noise. Values of “Prob>F” <0.0005 
indicate that model terms are significant. In this case A, B  and C are  the 
quadratic term of A2, B2 and C2 are significant model terms. Results of 
the equation indicate that the effect of B (concentration of cholesterol) is 
more significant than A and C. Two variables B and C have the negative 
effect on the entrapment efficiency, which means that these factors are 
inversely proportional to the response, whereas A has a positive effect on 
entrapment efficiency. The influence of the main and interactive effects 
of independent variables on the entrapment efficiency was further 
elucidated using the perturbation and 3D response surface plots. The 
individual main effects of A, B, and C on entrapment efficiency are shown 
in Fig. 6. It is found that all the variables are having interactive effects for 
the response Y2. The 3D response surface plots of the response Y2 are 
shown in Fig. 6 to depict the interactive effects of independent variables 
on response Y2; one variable was kept constant, while the other two 
variables varied in a certain range. The shapes of response surface plots 
reveal the nature and extent of the interaction between different factors. 
The interaction between A and B on entrapment efficiency at a fixed 
level of C is shown in Fig. 7. At low levels of A, Y2 reduced from 92.34% to 
56.1%. Similarly, at high levels of A, Y2 reduced from 96.12% to 62.18%. 
At low levels of B, Y2 reduced from 96.12% to 91.74%. Similarly, at 
high levels of B, Y2 reduced from 64.32% to 56.1%. At low levels of C, 
Y2 reduced from 91.74% to 59.72%. Similarly, at high levels of C, Y2 
reduced from 91.82% to 64.32%.
A numerical optimization technique using the desirability approach 
was employed to prepare atorvastatin proniosomes with the desired 
responses. Constraints such as minimizing the particle size in addition 
to maximizing the entrapment efficiency were set as goals to locate 
the optimum settings of independent variables. To verify these values, 
three batches of proniosomes were prepared according to the predicted 
levels of A, B, and C. The predicted and observed values are shown in 
Table 4. Obtained Y1 and Y2 values were in a close agreement with the 
predicted values. This demonstrated the reliability of the optimization 
procedure in predicting the operating parameters for the preparation of 
atorvastatin proniosomes. All the three batches of obtained atorvastatin 
proniosomes were subjected to further characterization.
The particle size of diluted proniosomes is shown in Table 5, and it 
ranges from 64.78±3.43 nm to 68.12±4.12 (Fig. 8) nm with unimodal 
particle size distribution, which favors transdermal delivery of 
atorvastatin. Since the smaller particle size is advantageous to decrease 
the irritation and improve the penetration of particles into the skin 
easily. All the proniosomal formulations were negatively charged, 
which was due to the negative charge present on the soya lecithin. The 
zeta potential values were high in all the formulations (Table 5 and 
Fig. 9). The high zeta potential increases the repulsion between the 
particles and thus prevents their aggregation and flocculation. Hence, 
it electrically stabilizes the system.
Surface morphology
Atorvastatin-loaded proniosomal gel formulation prepared using an 
optimum ratio of lecithin and cholesterol (9:1) demonstrated lamellar 
structures under a compound microscope (Fig. 10). Hydration of this gel 
with saline solution leads to swelling of bilayers as well as particles due 
Fig. 4: Perturbation plot showing the effect of A, B, and C on particle size
Fig. 5: Response surface plot showing the influence of the concentration of cholesterol and concentration of soya lecithin on particle size
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to the interaction of water with polar groups of surfactants. The bilayer 
tends to form spherical structure randomly giving rise to multilamellar, 
multivesicular structures. When shaken with aqueous phase, complete 
hydration takes place leading to the formation of proniosomes. 
Observation under an optical microscope revealed that proniosomal 
gel was progressively but rapidly converted to proniosomes almost 
completely within minutes.
Scanning electron microscope (SEM) for atorvastatin 
proniosomes
SEM studies of optimized formulation of atorvastain proniosomes 
revealed oval-shaped globules. The size is within nanometers. There 
are clear liquid droplets without any pores (Fig. 11).
TEM analysis
TEM analysis has demonstrated the presence of individual proniosomes 
in spherical shape. The images in Fig. 12 confirmed the proniosomal 
formation. TEM results were also compatible with atorvastatin particle 
size measurements.
Drug release study
From Fig. 13, it is clear that the cumulative release of drug from control 
was higher than from the proniosomes. This was because atorvastatin 
was sufficiently lipophilic and it partitions in favor of the proniosomes, 
which resulted in the slower release in a controlled manner of 
atorvastatin from proniosomes.
Release kinetics
Release data for optimized proniosomal formulation were fitted into 
various kinetic equations to find the order and mechanism of drug 
release. Kinetic analysis of drug release profiles showed that the systems 
predominantly released atorvastatin in a zero-order manner with a 
strong correlation coefficient (R2=0.9994) (Fig. 14). The optimized 
formulation of first-order plot and Higuchi plot is shown in Figs. 15 
and 16, respectively. This was corroborated by Korsmeyer–Peppas 
n=0.9053 (n>0.89) (Fig. 17) which implies super case II release kinetics 
(a strong indication of zero order). Zero-order release is the ideal in 
controlled drug release and has been reported not to be common with 
matrix systems; this is being attributed to time-dependant changes in 
drug-depleted matrix surface area and diffusional path length. Zero-
Fig. 6: Perturbation plot showing the effect of A, B, and C on entrapment efficiency
optimization and confirmation experiments
Fig. 7: Response surface plots showing the interactions between the concentration of surfactant and concentration of cholesterol on 
entrapment efficiency
Fig. 8: A graphical representation of particle size of atorvastatin optimized formulation
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order release has a lot of advantages including ability to deliver drug at 
a constant rate, thus providing a predictable bioavailability status. The 
results are summarized in Table 6.
Stability study
From stability studies, it indicates that no significant difference 
(p<0.05) was found in entrapment efficiency, particle size, and drug 
release data of optimized formulation stored at refrigerated conditions 
and room temperature.
Formulation of atorvastatin-based proniosomal hydrogel
Atorvastatin proniosomal hydrogel was prepared using Carbopol P 
934. An optimized batch of proniosomes was used for the preparation 
of atorvastatin-based proniosomal hydrogel by incorporating 
hydrated proniosomes to carbopol matrix. It is well known fact that 
the proniosomes get hydrated by skin moisture to form proniosomes, 
which have the ability to alter the transportation of drug across the 
skin. Adsorption and fusion of pronisome onto the skin surface would 
facilitate the permeation of drug, and barrier properties of stratum 
corneum are modified because non-ionic surfactant acts as penetration 
enhancers as it causes the disruption of tightly packed lipids that are 
filled in the extracellular spaces of stratum corneum. The pH of the final 
carbopol hydrogel formulation was found to be 7.18, hence the need 
Fig. 9: A graphical representation of zeta potential of atorvastatin optimized formulation
Fig. 10: Optical microscopy images of proniosomes formed on hydration of proniosomal gel at ×1000 magnification
Fig. 11: Scanning electron microscopy photographs of 
atorvastatin proniosomes
Fig. 12: Transmission electron microscopy image of atorvastatin 
optimized proniosomes
Fig. 13: In vitro release of atorvastatin from proniosomes
Fig. 14: Plot of zero-order release kinetics of the optimized batch
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to buffer the formulation with triethanolamine to a pH of 5.5. The 
viscosity of the final formulation was found to be 1590.66 cps which is 
within the acceptable limit.
The release rate (flux) of atorvastatin across the membrane and 
excised skin differs significantly (Table 7), which indicates about the 
barrier properties of skin. Interaction between skin and proniosomal 
component may justify these differences. Association and fusion of 
proniosomes to the skin surface resulted in higher flux due to the direct 
transfer of drug from the particles.
Skin irritation studies
The irritation studies were conducted with animal ethical committee 
approval bearing No:02/IAEC/VIPER/Ph.D/2017-18, on male Wistar 
rats (n=3). Formalin was applied as standard irritant. The rats were 
scored for erythema and edema scale [21,22]. The incidences of 
erythema and edema were significantly lower (0.18±0.112; p<0.05) in 
proniosomal formulation-treated rats than those treated with standard 
irritant, formalin. Hence, it was concluded that the formulations were 
non-irritant and safe.
CONCLUSION
This work has demonstrated the use of a 3-factor, 3-level Box–Behnken 
design, regression analysis, and contour plots in optimizing the 
formulation variables in the preparation of atorvastatin proniosomes 
by coacervation-phase separation method. Atorvastatin optimized 
proniosomal formulation F2 shown better drug release of 99.28% 
within 24 h in slow and controlled manner when compared with control. 
TEM analysis of optimized formulation has demonstrated the presence 
of individual proniosomes in spherical shape. Kinetic analysis of drug 
release profiles showed that the systems predominantly released 
atorvastatin in a zero-order manner with a strong correlation coefficient 
(R2=0.9994). This was corroborated by Korsmeyer–Peppas n=0.9053 
Fig. 15: Plot of first-order release kinetics of the optimized batch
Fig. 16: Plot of Higuchi release kinetics of the optimized batch
Fig. 17: Plot of Korsmeyer–Peppas release kinetics of the 
optimized batch
Table 4: Optimized values obtained by the constraints applied on Y1 and Y2
Independent variable Nominal 
values









Concentration of surfactant (A) 166.20 63.2398 97.74 F1 66.12 96.34
F2 65.72 97.42
Concentration of cholesterol (B) 17.46 F3 65.12 97.13
Concentration of soya lecithin (C) 103.94
Table 5: The mean particle size, PDI, entrapment efficiency, and 
zeta potential of optimized formulations
Batch MVS±SD (nm) PDI ZP±SD (mV) % EE±SD
1 66.12±1.62 0.712 -11.8±0.73 96.34±0.18
2 65.72±2.12 0.605 -10.5±0.18 97.42±0.37
3 65.12±1.13 0.782 -13.5±0.82 97.13±0.82
n=3 (p<0.05). SD: Standard deviation, PDI: Poly dispersibility index








R2 R2 R2 R2 n
F2 0.99945 0.69126 0.9090 0.9943 0.9053
Table 7: Flux of atorvastatin from proniosomes
Formulation Flux (μg cm−2 h−1)
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(n>0.89) which implies super case II release kinetics (a strong indication 
of zero order). The particle size and zeta potential of the optimized 
atorvastatin proniosomal gel were found to be 65.72 nm and −10.5 
mV, respectively. Zero-order release has a lot of advantages including 
ability to deliver drug at a constant rate, thus providing a predictable 
bioavailability status. An optimized batch of proniosomes was used 
for the preparation of atorvastatin-based proniosomal hydrogel by 
incorporating hydrated proniosomes to carbopol matrix to enhance the 
stability and viscosity of the system. The enhanced skin permeation, for 
a prolonged period of time, may lead to improved efficacy and better 
patient compliance than the conventional formulations.
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